Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008681 | 0.97 | HPGD (0.56) | HPGDPKMALDH1A1ADRB2POLB | |
| SCHEMBL4002284 | 0.94 | HPGD (0.53) | HPGDPKMALDH1A1ADRB2POLB | |
| SCHEMBL4001873 | 0.83 | RORC (0.48) | HPGDPOLBHTTMAPTTP53 | |
| SCHEMBL12231020 | 0.83 | TDP1 (0.55) | HPGDALDH1A1ADRB2POLBHTT | |
| SCHEMBL4001480 | 0.83 | HPGD (0.55) | HPGDALDH1A1POLBMAPTNPC1 | |
| SCHEMBL9153545 | 0.82 | ALDH1A1 (0.49) | ALDH1A1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6569544 | 0.82 | PKM (0.56) | HPGDPKMALDH1A1NPC1RAB9A | |
| SCHEMBL13102343 | 0.80 | ALDH1A1 (0.58) | ALDH1A1POLBMAPTNPC1RAB9A | |
| SCHEMBL12231179 | 0.79 | NPC1 (0.61) | HPGDPKMMAPTNPC1RAB9A | |
| SCHEMBL9809224 | 0.77 | HPGD (0.66) | HPGDPKMALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069286-B1 | INHIBITORS FOR GLYT-1 | HOFFMANN LA ROCHE (CH) | 2012-09-19 | — | — | EP | claimed |
| EP-2069286-A1 | INHIBITORS FOR GLYT-1 | F. Hoffmann-Roche AG (CH) | 2009-06-17 | — | — | EP | claimed |
| US-20080058331-A1 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. | 2008-03-06 | — | — | US | claimed |
| WO-2008025694-A1 | INHIBITORS FOR GLYT-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-06 | — | — | WO | claimed |
| EP-2069286-B1 | INHIBITORS FOR GLYT-1 | HOFFMANN LA ROCHE (CH) | 2012-09-19 | — | — | EP | disclosed |
| US-7589089-B2 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589089-B2 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. (US) | 2009-09-15 | — | — | US | disclosed |
| CN-101506148-A | Inhibitors for GLYT-1 | HOFFMANN LA ROCHE (CH) | 2009-08-12 | — | — | CN | disclosed |
| EP-2069286-A1 | INHIBITORS FOR GLYT-1 | F. Hoffmann-Roche AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| EP-2069286-A1 | INHIBITORS FOR GLYT-1 | F. Hoffmann-Roche AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| US-20080058331-A1 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058331-A1 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2008025694-A1 | INHIBITORS FOR GLYT-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008025694-A1 | INHIBITORS FOR GLYT-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058331-A1 | Inhibitors for GlyT-1 | GLRA1, SLC1A2, AGXT | HPGD 3821/4885PKM 2191/4885ALDH1A1 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.